Giovanna Bianchi ScarrÃ

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5328084/publications.pdf

Version: 2024-02-01

76 papers	4,324 citations	159585 30 h-index	110387 64 g-index
78 all docs	78 docs citations	78 times ranked	6064 citing authors

#	Article	IF	Citations
1	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	21.4	218
2	Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. International Journal of Cancer, 2015, 136, 1351-1360.	5.1	30
3	The 5â€²-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding. Oncotarget, 2015, 6, 39980-39994.	1.8	17
4	Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study. Journal of Investigative Dermatology, 2014, 134, 287-290.	0.7	18
5	Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nature Genetics, 2014, 46, 482-486.	21.4	283
6	Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer, 2013, 16, 596-601.	5.3	19
7	Prevalence of the <scp>E</scp>318<scp>K MITF</scp> germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell and Melanoma Research, 2013, 26, 259-262.	3.3	80
8	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	21.4	111
9	Clinical utility gene card for: Gorlin Syndrome - update 2013. European Journal of Human Genetics, 2013, 21, 1187-1187.	2.8	13
10	Hereditary trichilemmal cysts: a proposal for the assessment of diagnostic clinical criteria. Clinical Genetics, 2013, 84, 65-69.	2.0	18
11	Patched homolog 1 gene mutation (p.G1093R) induces nevoid basal cell carcinoma syndrome and non-syndromic keratocystic odontogenic tumors: A case report. Oncology Letters, 2012, 4, 241-244.	1.8	8
12	Duplication of CXC chemokine genes on chromosome 4q13 in a melanomaâ€prone family. Pigment Cell and Melanoma Research, 2012, 25, 243-247.	3.3	11
13	CDKN2Ais the main susceptibility gene in Italian pancreatic cancer families. Journal of Medical Genetics, 2012, 49, 164-170.	3.2	64
14	Ameloblastoma: a neglected criterion for nevoid basal cell carcinoma (Gorlin) syndrome. Familial Cancer, 2012, 11, 411-418.	1.9	19
15	Unicystic ameloblastoma associated with the novel K729M PTCH1 mutation in a patient with nevoid basal cell carcinoma (Gorlin) syndrome. Cancer Genetics, 2012, 205, 177-181.	0.4	10
16	Novel PTCH1 Mutations in Patients with Keratocystic Odontogenic Tumors Screened for Nevoid Basal Cell Carcinoma (NBCC) Syndrome. PLoS ONE, 2012, 7, e43827.	2.5	20
17	Brookeâ€Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumorâ€suppressor genes. Journal of Cutaneous Pathology, 2012, 39, 366-371.	1.3	25
18	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Familial Cancer, 2012, 11, 41-47.	1.9	32

#	Article	IF	Citations
19	On the Interplay of Telomeres, Nevi and the Risk of Melanoma. PLoS ONE, 2012, 7, e52466.	2.5	18
20	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	21.4	230
21	Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunosuppression. PLoS ONE, 2011, 6, e29451.	2.5	18
22	Clinical utility gene card for: Gorlin syndrome. European Journal of Human Genetics, 2011, 19, 3-3.	2.8	6
23	A Flexible Multiplex Bead-Based Assay for Detecting Germline CDKN2A and CDK4 Variants in Melanoma-Prone Kindreds. Journal of Investigative Dermatology, 2011, 131, 480-486.	0.7	11
24	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 2011, 43, 1114-1118.	21.4	140
25	The role of AIRE polymorphisms in melanoma. Clinical Immunology, 2010, 136, 96-104.	3.2	23
26	Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. Journal of the National Cancer Institute, 2010, 102, 1568-1583.	6.3	108
27	Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations. Journal of Investigative Dermatology, 2010, 130, 618-620.	0.7	37
28	Identification of aSUFUgermline mutation in a family with Gorlin syndrome. American Journal of Medical Genetics, Part A, 2009, 149A, 1539-1543.	1.2	163
29	Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Familial Cancer, 2009, 8, 547-553.	1.9	34
30	MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatric Blood and Cancer, 2009, 53, 576-583.	1.5	17
31	Analysis of Cultured Human Melanocytes Based on Polymorphisms within the SLC45A2/MATP, SLC24A5/NCKX5, and OCA2/P Loci. Journal of Investigative Dermatology, 2009, 129, 392-405.	0.7	96
32	Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 2009, 41, 920-925.	21.4	422
33	Five novel germline functionâ€impairing mutations of CYLD in Italian patients with multiple cylindromas. Clinical Genetics, 2009, 76, 481-485.	2.0	15
34	Selection criteria for genetic assessment of patients with familial melanoma. Journal of the American Academy of Dermatology, 2009, 61, 677.e1-677.e14.	1.2	154
35	Clinical genetic testing for familial melanoma in Italy: A cooperative study. Journal of the American Academy of Dermatology, 2009, 61, 775-782.	1.2	45
36	CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Research, 2009, 19, 142-145.	1.2	20

#	Article	IF	Citations
37	A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). European Journal of Cancer, 2008, 44, 1269-1274.	2.8	26
38	CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell and Melanoma Research, 2008, 21, 700-709.	3.3	46
39	No Evidence for Linkage with Melanoma in Italian Melanoma-Prone Families. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1838-1840.	2.5	2
40	Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. Melanoma Research, 2008, 18, 431-437.	1.2	9
41	Predicting the Risk of Pancreatic Cancer: On CDKN2A Mutations in the Melanoma-Pancreatic Cancer Syndrome in Italy. Journal of Clinical Oncology, 2007, 25, 5336-5337.	1.6	26
42	Cutaneous phenotype andMC1R variants as modifying factors for the development of melanoma inCDKN2A G101W mutation carriers from 4 countries. International Journal of Cancer, 2007, 121, 825-831.	5.1	45
43	High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. Cancer Research, 2006, 66, 9818-9828.	0.9	373
44	Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. Journal of Medical Genetics, 2006, 44, 99-106.	3.2	350
45	Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Human Molecular Genetics, 2006, 15, 2682-2689.	2.9	41
46	Increased Risk of Colorectal Adenomas in Italian Subjects Carrying the p53 PIN3 A2-Pro72 Haplotype. Digestion, 2006, 74, 228-235.	2.3	19
47	Nevoid Basal Cell Carcinoma Syndrome in infants: improving diagnosis. Child: Care, Health and Development, 2005, 31, 351-354.	1.7	8
48	INK4/ARF germline alterations in pancreatic cancer patients. Annals of Oncology, 2004, 15, 70-78.	1.2	45
49	Novel MC1R variants in Ligurian melanoma patients and controls. Human Mutation, 2004, 24, 103-103.	2.5	41
50	Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Human Pathology, 2004, 35, 25-33.	2.0	49
51	Inverse correlation between p16INK4A expression and NF-ÎºB activation in melanoma progression. Human Pathology, 2004, 35, 1029-1037.	2.0	13
52	Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Research, 2004, 14, 443-448.	1.2	26
53	Genetic testing for melanoma. Lancet Oncology, The, 2002, 3, 653-654.	10.7	106
54	Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect. Genes Chromosomes and Cancer, 2001, 32, 195-202.	2.8	63

#	Article	IF	Citations
55	Characterization of a triplex DNA-binding protein encoded by an alternative reading frame of loricrin. FEBS Journal, 2001, 268, 225-234.	0.2	0
56	The yeast CDP1 gene encodes a triple-helical DNA-binding protein. Nucleic Acids Research, 2000, 28, 4090-4096.	14.5	34
57	A Single Genetic Origin for the G101W CDKN2A Mutation in 20 Melanoma-Prone Families. American Journal of Human Genetics, 2000, 67, 311-319.	6.2	80
58	Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. , 1999, 83, 441-448.		78
59	Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions. Melanoma Research, 1999, 9, 253-260.	1.2	8
60	An upstream negative regulatory element in human granulocyte-macrophage colony-stimulating factor promoter is recognised by AP1 family members. FEBS Letters, 1998, 440, 119-124.	2.8	5
61	c-Rel and p65 subunits bind to an upstream NF-ÎºB site in human granulocyte macrophage-colony stimulating factor promoter involved in phorbol ester response in 5637 cells. FEBS Letters, 1997, 418, 215-218.	2.8	10
62	An Upstream Positive Regulatory Element in Human GM-CSF Promoter Is Recognized by NF-ÎºB/Rel Family Members. Biochemical and Biophysical Research Communications, 1996, 223, 64-72.	2.1	27
63	MEL-P, a GM-CSF-producing human melanoma cell line. Melanoma Research, 1996, 6, 203-213.	1.2	6
64	Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Research, 1995, 5, 41-47.	1.2	35
65	Characterization of a Distal 5â€²-Flanking Region (â^'2010/â^'630) of Human GM-CSF. Biochemical and Biophysical Research Communications, 1995, 214, 1015-1022.	2.1	5
66	Expression and Genomic Configuration of GM-CSF, IL-3, M-CSF Receptor (C-FMS), Early Growth Response Gene-1 (EGR-1) and M-CSF Genes in Primary Myelodysplastic Syndromes. Leukemia and Lymphoma, 1994, 15, 135-141.	1.3	5
67	H and L Ferritin Gene Expression in U937 Cells Induced to Macrophage Differentiation. Leukemia and Lymphoma, 1993, 12, 109-115.	1.3	4
68	Lactoferrin binding sites and nuclear localization in K562(S) cells. Journal of Cellular Physiology, 1992, 153, 477-482.	4.1	98
69	Electrophoretic pattern of NADPH-dependent oxidoreductive activities in K 562 and HL 60 leukemic cell lines. Cell Differentiation, 1988, 22, 155-158.	0.4	1
70	Characterization, localization, and biosynthesis of acetylcholinesterase in K 562 cells. Archives of Biochemistry and Biophysics, 1988, 267, 245-251.	3.0	4
71	Effect of endothelial cell conditioned medium on the growth of human bone marrow fibroblasts. Journal of Cellular Physiology, 1985, 123, 343-346.	4.1	8
72	Unusual Ph translocations in CML: Four new cases. Cancer Genetics and Cytogenetics, 1985, 15, 199-207.	1.0	22

#	Article	IF	Citations
73	Masked Philadelphia chromosome caused by translocation (9;11;22). Cancer Genetics and Cytogenetics, 1983, 8, 319-323.	1.0	20
74	Marked karyotype abnormalities in two cases of acute myelogenous leukemia. Cancer Genetics and Cytogenetics, 1981, 4, 303-309.	1.0	8
75	Karyotype evolution in a case of chronic myelogenous leukemia with an unusual Philadelphia chromosome translocation, t(4;22), and an additional translocation, t(3;5). Cancer Genetics and Cytogenetics, 1981, 3, 47-53.	1.0	13
76	A case of chronic myelogenous leukemia with unusual chromosomal abnormality. Leukemia Research, 1979, 3, 271-275.	0.8	8